The myths and realities of portopulmonary hypertension

Link to article at PubMed

Hepatology. 2020 Jun 9. doi: 10.1002/hep.31415. Online ahead of print.


Portopulmonary hypertension (POPH), defined as an increased mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR) in the setting of portal hypertension, is a commonly misunderstood pulmonary vascular complication of liver disease. Recent literature has expanded our knowledge regarding disease pathogenesis, the role of pulmonary arterial hypertension (PAH) targeted therapy and liver transplantation (LT) in management, and long-term outcomes. However, many myths and misconceptions regarding POPH prognosis and treatment remain. The aim of this review is to examine the prevailing myths and current realities regarding POPH.

PMID:32515501 | DOI:10.1002/hep.31415

Leave a Reply

Your email address will not be published.